Transforming growth factor-beta-activated kinase 1 (TAK1) (TAK1)

Transforming growth factor-beta-activated kinase 1 (TAK1), also known as MAP3K7, is a pivotal serine/threonine kinase that functions as a central integrator of signals from various receptors, including TGF-beta, TNF, IL-1, and Toll-like receptors [1, 2]. It plays a critical role in the activation of the NF-kappaB and mitogen-activated protein kinase (MAPK) pathways, specifically the JNK and p38 cascades, which regulate inflammation, immune responses, and cell survival [2, 4]. In many pathological conditions, such as rheumatoid arthritis and various cancers, TAK1 is overactivated, promoting chronic inflammation and resistance to apoptosis [4]. Consequently, TAK1 has emerged as a significant therapeutic target, with small molecule inhibitors like Takinib being developed to sensitize cancer cells to TNF-induced death and reduce inflammatory cytokine production [3]. However, because TAK1 is essential for maintaining tissue homeostasis, particularly in the liver and intestines, its systemic inhibition carries risks of toxicity and cell death in healthy tissues [2]. [1] UniProt Consortium. MAP3K7 - Mitogen-activated protein kinase kinase kinase 7. https://www.uniprot.org/uniprotkb/P43354/entry [2] Mihaly, S. R., et al. (2014). TAK1 control of cell death. Cell Death & Differentiation. https://doi.org/10.1038/cdd.2014.123 [3] Totzke, J., et al. (2017). Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-alpha Inhibition. Cell Chemical Biology. https://doi.org/10.1016/j.chembiol.2017.07.011 [4] Ajibade, A. A., et al. (2013). TAK1, a bridge between inflammation and cancer. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-012-0988-0

Other names

Mitogen-activated protein kinase kinase kinase 7MAP3K7TGF-beta-activated kinase 1TAK1/MAPK pathway

Small molecule inhibition of the TAK1 kinase domain, preventing the phosphorylation of downstream MKKs (MKK3/6 and MKK4/7) and the IKK complex, thereby blocking the activation of p38, JNK, and NF-kappaB signaling pathways.